Trial Profile
A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ACP 01 (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial disorders
- Focus Therapeutic Use
- Sponsors Hemostemix
- 26 Jan 2020 According to a Hemostemix Inc. media release, company anticipates that it will conduct a futility analysis for potentially stopping enrolment in the clinical trial when 42 subjects have completed at least 26 weeks of follow-up.
- 30 Apr 2019 Status changed from recruiting to suspended.
- 27 Apr 2018 According to a Hemostemix Inc. media release,The Company recently announced that it received FDA approval in the United States in addition to Health Canada approval for its clinical trial in Canada.